FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051665090> ?p ?o ?g. }

• W2051665090 endingPage "531" @default.
• W2051665090 startingPage "523" @default.
• W2051665090 abstract "Adjuvant hormonal therapy for hormone receptor (HR)-positive primary breast cancer patients and a human epidermal growth factor receptor 2 (HER2)-targeted agent for HER2-positive primary breast cancer patients are standard treatment. However, it is not well known whether adding hormonal therapy to the combination of preoperative or postoperative chemotherapy and HER2-targeted agent contributes any additional clinical benefit in patients with HR-positive/HER2-positive primary breast cancer regardless of cross-talk between HR and HER2. We retrospectively reviewed records from 897 patients with HR-positive/HER2-positive primary breast cancer with clinical stage I-III disease who underwent surgery between 1988 and 2009. We determined the overall survival (OS) and disease-free survival (DFS) rates according to whether they received hormonal therapy or not and according to the type of hormonal therapy, tamoxifen and aromatase inhibitor, they received. The median followup time was 52.8 months (range 1-294.6 months). Patients who received hormonal therapy with chemotherapy and trastuzumab (n = 128) had significantly higher OS and DFS rates than did those who received only chemotherapy and trastuzumab (n = 46) in log-rank analysis (OS 96.1 vs. 87.0 %, p = 0.023, DFS 86.7 vs. 78.3 %, p = 0.029). There was no statistical difference in OS or DFS between those given an aromatase inhibitor and those given tamoxifen. In multivariate analysis, receiving hormonal therapy in addition to the combination of chemotherapy and trastuzumab was the sole independent prognostic factor for DFS (hazard ratio 0.446; 95 % CI 0.200-0.992; p = 0.048), and there was a similar trend in OS. Our study supported that hormonal therapy, whether in the form of an aromatase inhibitor or tamoxifen, confers a survival benefit when added to chemotherapy and trastuzumab in patients with HR-positive/HER2-positive primary breast cancer. Adjuvant treatment without hormonal therapy is inferior for this patient population." @default.
• W2051665090 created "2016-06-24" @default.
• W2051665090 creator A5015450747 @default.
• W2051665090 creator A5017227852 @default.
• W2051665090 creator A5084241748 @default.
• W2051665090 creator A5085550715 @default.
• W2051665090 creator A5088814426 @default.
• W2051665090 date "2012-11-27" @default.
• W2051665090 modified "2023-09-22" @default.
• W2051665090 title "Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer" @default.
• W2051665090 cites W1595886999 @default.
• W2051665090 cites W1961026612 @default.
• W2051665090 cites W1987326983 @default.
• W2051665090 cites W2038451517 @default.
• W2051665090 cites W2062713892 @default.
• W2051665090 cites W2081923162 @default.
• W2051665090 cites W2095156669 @default.
• W2051665090 cites W2095342969 @default.
• W2051665090 cites W2111253826 @default.
• W2051665090 cites W2114974083 @default.
• W2051665090 cites W2130900820 @default.
• W2051665090 cites W2131964282 @default.
• W2051665090 cites W2135278339 @default.
• W2051665090 cites W2137355132 @default.
• W2051665090 cites W2137853125 @default.
• W2051665090 cites W2138317169 @default.
• W2051665090 cites W2140055441 @default.
• W2051665090 cites W2141232624 @default.
• W2051665090 cites W2142739119 @default.
• W2051665090 cites W2145257123 @default.
• W2051665090 cites W2146378328 @default.
• W2051665090 cites W2155803397 @default.
• W2051665090 cites W2165432902 @default.
• W2051665090 cites W2318605753 @default.
• W2051665090 doi "https://doi.org/10.1007/s10549-012-2336-6" @default.
• W2051665090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3860360" @default.
• W2051665090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23184079" @default.
• W2051665090 hasPublicationYear "2012" @default.
• W2051665090 type Work @default.
• W2051665090 sameAs 2051665090 @default.
• W2051665090 citedByCount "26" @default.
• W2051665090 countsByYear W20516650902013 @default.
• W2051665090 countsByYear W20516650902014 @default.
• W2051665090 countsByYear W20516650902015 @default.
• W2051665090 countsByYear W20516650902016 @default.
• W2051665090 countsByYear W20516650902018 @default.
• W2051665090 countsByYear W20516650902019 @default.
• W2051665090 countsByYear W20516650902020 @default.
• W2051665090 countsByYear W20516650902021 @default.
• W2051665090 countsByYear W20516650902022 @default.
• W2051665090 crossrefType "journal-article" @default.
• W2051665090 hasAuthorship W2051665090A5015450747 @default.
• W2051665090 hasAuthorship W2051665090A5017227852 @default.
• W2051665090 hasAuthorship W2051665090A5084241748 @default.
• W2051665090 hasAuthorship W2051665090A5085550715 @default.
• W2051665090 hasAuthorship W2051665090A5088814426 @default.
• W2051665090 hasBestOaLocation W20516650902 @default.
• W2051665090 hasConcept C121608353 @default.
• W2051665090 hasConcept C126322002 @default.
• W2051665090 hasConcept C143998085 @default.
• W2051665090 hasConcept C207103383 @default.
• W2051665090 hasConcept C2776694085 @default.
• W2051665090 hasConcept C2777176818 @default.
• W2051665090 hasConcept C2777982462 @default.
• W2051665090 hasConcept C2778311097 @default.
• W2051665090 hasConcept C2778504769 @default.
• W2051665090 hasConcept C2779786085 @default.
• W2051665090 hasConcept C2780275930 @default.
• W2051665090 hasConcept C29456083 @default.
• W2051665090 hasConcept C44249647 @default.
• W2051665090 hasConcept C530470458 @default.
• W2051665090 hasConcept C71924100 @default.
• W2051665090 hasConceptScore W2051665090C121608353 @default.
• W2051665090 hasConceptScore W2051665090C126322002 @default.
• W2051665090 hasConceptScore W2051665090C143998085 @default.
• W2051665090 hasConceptScore W2051665090C207103383 @default.
• W2051665090 hasConceptScore W2051665090C2776694085 @default.
• W2051665090 hasConceptScore W2051665090C2777176818 @default.
• W2051665090 hasConceptScore W2051665090C2777982462 @default.
• W2051665090 hasConceptScore W2051665090C2778311097 @default.
• W2051665090 hasConceptScore W2051665090C2778504769 @default.
• W2051665090 hasConceptScore W2051665090C2779786085 @default.
• W2051665090 hasConceptScore W2051665090C2780275930 @default.
• W2051665090 hasConceptScore W2051665090C29456083 @default.
• W2051665090 hasConceptScore W2051665090C44249647 @default.
• W2051665090 hasConceptScore W2051665090C530470458 @default.
• W2051665090 hasConceptScore W2051665090C71924100 @default.
• W2051665090 hasIssue "2" @default.
• W2051665090 hasLocation W20516650901 @default.
• W2051665090 hasLocation W20516650902 @default.
• W2051665090 hasLocation W20516650903 @default.
• W2051665090 hasLocation W20516650904 @default.
• W2051665090 hasOpenAccess W2051665090 @default.
• W2051665090 hasPrimaryLocation W20516650901 @default.
• W2051665090 hasRelatedWork W1984699041 @default.
• W2051665090 hasRelatedWork W2045823922 @default.
• W2051665090 hasRelatedWork W2049746519 @default.
• W2051665090 hasRelatedWork W2114147029 @default.

• next